Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : ForDoz
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Introduces Doxorubicin Hydrochloride Liposome Injection in US
Details : Doxorubicin hydrochloride is a DNA Topoisomerase-II inhibitor, indicated for the treatment of ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma.
Product Name : Doxil-Generic
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
August 29, 2024
Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : ForDoz
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Announces Achievement of Key Milestone for its Phase 1 Clinical Stage MALT 1 Inhibitor Program
Details : Lupin and AbbVie inked the licensing, development, and commercialization agreement for its novel MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program to treat Hematological Cancers.
Product Name : ABBV-525
Product Type : Other Small Molecule
Upfront Cash : $30.0 million
June 29, 2023
Lead Product(s) : LNP3794,BI 1701963
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $50.0 million
Deal Type : Collaboration
Lupin Announces Achievement of Key Milestones for its Clinical Stage MEK Inhibitor Compound
Details : Lupin’s proprietary MEK inhibitor compound is planned for clinical development in combination with Boehringer Ingelheim’s KRAS inhibitor pipeline to address KRAS-driven cancers.
Product Name : BI 3011441
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 27, 2021
Lead Product(s) : LNP3794,BI 1701963
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $50.0 million
Deal Type : Collaboration
Reset All
